Related references
Note: Only part of the references are listed.Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter
Roberto Ferrara et al.
CLINICAL CANCER RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer
Alessandra Metelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B. Holmgaard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
Chaido Stathopoulou et al.
IMMUNITY (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011+/- nivolumab (nivo) in patients (pts) with advanced cancers.
Timothy Anthony Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
Ravit Geva et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.
Yosuke Togashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tissue-Specific Roles of NKT Cells in Tumor Immunity
Masaki Terabe et al.
FRONTIERS IN IMMUNOLOGY (2018)
Heat Shock Proteins as Immunomodulants
Tawanda Zininga et al.
MOLECULES (2018)
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
Yasuko Tada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori
Hirotsugu Nagase et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Jason B. Williams et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Foxp3-independent mechanism by which TGF-β controls peripheral T cell tolerance
Soyoung A. Oh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Rina M. Mbofung et al.
NATURE COMMUNICATIONS (2017)
Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction
Emily J. Colbeck et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer A Randomized Clinical Trial
Martin Scurr et al.
JAMA ONCOLOGY (2017)
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor
Tomasz Maj et al.
NATURE IMMUNOLOGY (2017)
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer
Martin Scurr et al.
CLINICAL CANCER RESEARCH (2017)
Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).
Raphael Buena et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
Shamim Ahmad et al.
CANCER RESEARCH (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone et al.
IMMUNITY (2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
Baihao Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
Kazuhide Sato et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma
Ilona Kryczek et al.
ONCOIMMUNOLOGY (2016)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Koji Kurose et al.
CLINICAL CANCER RESEARCH (2015)
Regulatory B Cells: Origin, Phenotype, and Function
Elizabeth C. Rosser et al.
IMMUNITY (2015)
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F. Jones et al.
INVESTIGATIONAL NEW DRUGS (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1
Peter Hsu et al.
JOURNAL OF IMMUNOLOGY (2015)
PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells
Hyo Jin Park et al.
JOURNAL OF IMMUNOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy
David A. Proia et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3+ and Foxp3- T cells
Dean Franckaert et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3
Reiner K. W. Mailer et al.
SCIENTIFIC REPORTS (2015)
Function of a Foxp3 cis-Element in Protecting Regulatory T Cell Identity
Xudong Li et al.
CELL (2014)
Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus
Yongqiang Feng et al.
CELL (2014)
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
J. Christoph Vahl et al.
IMMUNITY (2014)
The role of T-cell receptor recognition of peptide:MHC complexes in the formation and activity of Foxp3+ regulatory T cells
Katherine A. Weissler et al.
IMMUNOLOGICAL REVIEWS (2014)
TGF-β: Duality of Function Between Tumor Prevention and Carcinogenesis
Daniel R. Principe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Continuous requirement for the TCR in regulatory T cell function
Andrew G. Levine et al.
NATURE IMMUNOLOGY (2014)
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Desiree Schubert et al.
NATURE MEDICINE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Foxp3 Expression in Macrophages Associated with RENCA Tumors in Mice
Christel Devaud et al.
PLOS ONE (2014)
Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma
Eleonora Reginato et al.
PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES (2014)
Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation
Hiromasa Morikawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals
Yuka Maeda et al.
SCIENCE (2014)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Hye Sun Kuehn et al.
SCIENCE (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Foxp3 Transcription Factor Is Proapoptotic and Lethal to Developing Regulatory T Cells unless Counterbalanced by Cytokine Survival Signals
Xuguang Tai et al.
IMMUNITY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Koji Atarashi et al.
NATURE (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
Sven Malchow et al.
SCIENCE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Lack of Foxp3+ macrophages in both untreated and B16 melanoma-bearing mice
Christian T. Mayer et al.
BLOOD (2012)
Macrophages have no lineage history of Foxp3 expression
Stephanie Put et al.
BLOOD (2012)
T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion
James P. Hindley et al.
CANCER RESEARCH (2012)
Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells
Aparna Rao et al.
CANCER RESEARCH (2012)
The T-cell Receptor Repertoire of Tumor-Infiltrating Regulatory T Lymphocytes Is Skewed Toward Public Sequences
Alexander Sainz-Perez et al.
CANCER RESEARCH (2012)
Foxp3 Exploits a Pre-Existent Enhancer Landscape for Regulatory T Cell Lineage Specification
Robert M. Samstein et al.
CELL (2012)
Allergen-specific responses of CD19(+)CD5(+)Foxp3(+) regulatory B cells (Bregs) and CD4(+)Foxp3(+) regulatory T cell (Tregs) in immune tolerance of cow milk allergy of late eczematous reactions
Joonyong Noh et al.
CELLULAR IMMUNOLOGY (2012)
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Reinhart Speeckaert et al.
EUROPEAN JOURNAL OF CANCER (2012)
T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are Independent and Complementary Events Required for Treg Cell Development
Naganari Ohkura et al.
IMMUNITY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Novel Foxo1-dependent transcriptional programs control Treg cell function
Weiming Ouyang et al.
NATURE (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HSP70 Enhances Immunosuppressive Function of CD4+CD25+FoxP3+ T Regulatory Cells and Cytotoxicity in CD4+CD25- T Cells
Julian Wachstein et al.
PLOS ONE (2012)
Regulatory T Cells Increase the Avidity of Primary CD8+ T Cell Responses and Promote Memory
Luigia Pace et al.
SCIENCE (2012)
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Andrew J. Rech et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Courtney Smith et al.
CANCER DISCOVERY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors
James P. Hindley et al.
CANCER RESEARCH (2011)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Eric V. Dang et al.
CELL (2011)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Ingrid M. E. Desar et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions
Yeonseok Chung et al.
NATURE MEDICINE (2011)
Foxp3+ follicular regulatory T cells control the germinal center response
Michelle A. Linterman et al.
NATURE MEDICINE (2011)
Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human
Fabian Birzele et al.
NUCLEIC ACIDS RESEARCH (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
Joannes F. M. Jacobs et al.
CLINICAL CANCER RESEARCH (2010)
Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells
Yohsuke Harada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
OX40 is required for regulatory T cell-mediated control of colitis
Thibault Griseri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Identification of Regulatory Foxp3+ Invariant NKT Cells Induced by TGF-β
Marta Monteiro et al.
JOURNAL OF IMMUNOLOGY (2010)
Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses
Dominique B. Hoelzinger et al.
JOURNAL OF IMMUNOLOGY (2010)
A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells
Derese Getnet et al.
MOLECULAR IMMUNOLOGY (2010)
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Kajsa Wing et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FOXP3+ regulatory T cells in the human immune system
Shimon Sakaguchi et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate
Lizhong Wang et al.
CANCER CELL (2009)
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Ilona Kryczek et al.
CANCER RESEARCH (2009)
Global Mapping of H3K4me3 and H3K27me3 Reveals Specificity and Plasticity in Lineage Fate Determination of Differentiating CD4+ T Cells
Gang Wei et al.
IMMUNITY (2009)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
Jeffrey M. Wilson et al.
JOURNAL OF IMMUNOLOGY (2009)
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
Marcus C. B. Tan et al.
JOURNAL OF IMMUNOLOGY (2009)
The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation
Meghan A. Koch et al.
NATURE IMMUNOLOGY (2009)
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
Christina L. Roland et al.
PLOS ONE (2009)
CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner
Ashutosh Chaudhry et al.
SCIENCE (2009)
Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition
Milka Sarris et al.
IMMUNITY (2008)
Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire
Matthew A. Burchill et al.
IMMUNITY (2008)
A two-step process for thymic regulatory T cell development
Chan-Wang Joaquim Lio et al.
IMMUNITY (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer
Yukiko Kiniwa et al.
CLINICAL CANCER RESEARCH (2007)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
Mary T. Litzinger et al.
BLOOD (2007)
Induction of FOXP3 expression in naive human CD4+FOXP3- T cells by T-cell receptor stimulation is transforming growth factor-β-dependent but does not confer a regulatory phenotype
Dat Q. Tran et al.
BLOOD (2007)
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism
Janine L. Coombes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma
Shuang Wei et al.
CANCER RESEARCH (2007)
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene
Tao Zuo et al.
CELL (2007)
Depletion of CD4+CD25+ human regulatory T cells in vivo:: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
Karsten Mahnke et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Interleukin-7 receptor expression: intelligent design
Renata Mazzucchelli et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Jeong M. Kim et al.
NATURE IMMUNOLOGY (2007)
Epigenetic control of the foxp3 locus in regulatory T cells
Stefan Floess et al.
PLOS BIOLOGY (2007)
IL-2 receptor β-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells
Matthew A. Burchill et al.
JOURNAL OF IMMUNOLOGY (2007)
Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor:: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells
Andrew G. Jarnicki et al.
JOURNAL OF IMMUNOLOGY (2006)
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Weihong Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells
Nabila Seddiki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
IFN-γ, controls the generation/activation of CD4+CD25+ regulatory T cells in antitumor immune response
H Nishikawa et al.
JOURNAL OF IMMUNOLOGY (2005)
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity:: a novel regulatory role for OX40 and its comparison with GITR
B Valzasina et al.
BLOOD (2005)
De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4-CD25- cells
MR Walker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
H Nishikawa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Human T regulatory cells can use the perforin pathway to cause autologous target cell death
WJ Grossman et al.
IMMUNITY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors
CS Hsieh et al.
IMMUNITY (2004)
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals
LH Zou et al.
CANCER RESEARCH (2004)
An essential role for Scurfin in CD4+CD25+ T regulatory cells
R Khattri et al.
NATURE IMMUNOLOGY (2003)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide
MS Jordan et al.
NATURE IMMUNOLOGY (2001)
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse
ME Brunkow et al.
NATURE GENETICS (2001)
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
CL Bennett et al.
NATURE GENETICS (2001)
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
B Salomon et al.
IMMUNITY (2000)
Share Paper
